Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01555125 · ClinicalTrials.gov registry record · Phase 3
First Study of Secukinumab in Pre-filled Syringes in Subjects With Chronic Plaque-type Psoriasis: Response at 12 Weeks
A Phase 3 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 177
- Enrollment target
NCT01555125 is a Phase 3 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 177 participants.
The verdict
NCT01555125, a Phase 3 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 177 participants
- Enrollment target
Study Summary
The purpose of this study is to demonstrate efficacy of secukinumab at Week 12 based on PASI and IGA response rates versus placebo in subjects with moderate to severe chronic plaque-type psoriasis.
Interventions
- DRUG placebo
- DRUG secukinumab 150 mg
- DRUG secukinumab 300 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 177 participants |
| Start Date | 2012-05-08 |
| Est. Completion | 2016-10-24 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01555125
The ClinicalTrials.gov registry entry for NCT01555125 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 177 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which placebo is the first listed.
NCT01555125 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01555125 about?
NCT01555125 is a clinical study titled "First Study of Secukinumab in Pre-filled Syringes in Subjects With Chronic Plaque-type Psoriasis: Response at 12 Weeks". The purpose of this study is to demonstrate efficacy of secukinumab at Week 12 based on PASI and IGA response rates versus placebo in subjects with moderate to severe chronic plaque-type psoriasis.
What is the current status of trial NCT01555125?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 177 participants. The study started on 2012-05-08. Estimated completion is 2016-10-24.
What interventions are being tested in trial NCT01555125?
The interventions under investigation include: placebo (DRUG), secukinumab 150 mg (DRUG), secukinumab 300 mg (DRUG).
Who is sponsoring clinical trial NCT01555125?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.